Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Venus Medtech (Hangzhou)'s OCF Margin % or its related term are showing as below:
VMTHF'
s OCF Margin % Range Over the Past 10 Years
Min: -452.9 Med: -124.15 Max: 5.04
Current: -105.27
During the past 9 years, the highest OCF Margin % of Venus Medtech (Hangzhou) was 5.04%. The lowest was -452.90%. And the median was -124.15%.
VMTHF's OCF Margin % is ranked worse than 85.29% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 5.745
vs VMTHF: -105.27
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Medtech (Hangzhou) OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s OCF Margin % distribution charts can be found below:
* The bar in red indicates where Venus Medtech (Hangzhou)'s OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Venus Medtech (Hangzhou) (VMTHF) has a OCF Margin % of -174.62% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Venus Medtech (Hangzhou) and its competitors. According to the industry distribution chart, Venus Medtech (Hangzhou) ranks #696 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 85.3%.
Is Venus Medtech (Hangzhou)'s OCF Margin % too high?
Venus Medtech (Hangzhou)'s current OCF Margin % is -174.62%. Based on the distribution chart, Venus Medtech (Hangzhou) ranks #696 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Venus Medtech (Hangzhou) has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Venus Medtech (Hangzhou)'s OCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Venus Medtech (Hangzhou) ranks #696 out of 816 companies for OCF Margin %. This places Venus Medtech (Hangzhou) in the lower half of its industry. The industry median OCF Margin % is 5.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.75, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Venus Medtech (Hangzhou) and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venus Medtech (Hangzhou)'s current OCF Margin % is -174.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Medtech (Hangzhou) stock overvalued right now?
Venus Medtech (Hangzhou) (VMTHF) has a current OCF Margin % of -174.62%. The stock's GF Value™ is $1.27, compared to a current price of $0.42 — trading 66.8% below its estimated fair value. The current OCF Margin % is -174.62%. Venus Medtech (Hangzhou)'s overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Venus Medtech (Hangzhou) (VMTHF), the current OCF Margin % is -174.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Venus Medtech (Hangzhou) (VMTHF) Overvalued in 2026?
Based on GuruFocus' analysis, Venus Medtech (Hangzhou) stock appears to be undervalued.
The current stock price of $0.42 is trading 66.8% below its estimated GF Value™ of $1.27.
Key valuation signals for VMTHF:
OCF Margin %: -174.62%
GF Value™: $1.27 vs. price of $0.42 (66.8% below fair value)
No single metric tells the full story. See the VMTHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Venus Medtech (Hangzhou) Inc is engaged in the medical devices that integrate R&D, clinical development, manufacturing, and commercialization. The company has developed a product portfolio covering the interventional devices for valvular heart diseases, including transcatheter aortic valve replacement (TAVR), transcatheter pulmonary valve replacement (TPVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), and other procedural accessories, allowing it to provide overall solutions for physicians and patients. Geographically, the company operates in mainland China, Israel, Hong Kong, the USA, and the Netherlands. The majority of the revenue is derived from Mainland China.
52GF Score
Get the complete analysis for VMTHF
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VMTHF has been successfully added to your 
